CABA · Cabaletta Bio, Inc.
$1.99
-0.03 (-1.49%)
At close · Oct 7
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“we have concluded that substantial doubt exists about the Company’s ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$335.70M
Shares
169.55M
Volume · Oct 6
4.13M
Avg daily vol (3M)
4.81M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.02
Open$2.10
Day$1.96–2.14
52W close$1.89–4.15
Avg vol 30d5.8M
Short int33.3M · 19.7% float · 5.2d
Short vol50%
Last earningsNov 14, 2024
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$181.32M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-45.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$225.10M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+144.3%
Year over year · more shares
Price change (1Y)
-17.2%
Trailing year
Short interest
19.7%
Latest settlement · 5.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−31%
below
Price vs 50-day avg
−26%
below
RSI (14)
34
neutral
MACD trend
Negative
52-week position
6%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−38%
trailing
6-month return
−41%
trailing
YTD return
−8%
this year
Relative strength
−52%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+27% holders QoQ · +52 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
19.66% of float · ▼ -19.6% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
142 holders — mid 3-yr range
Squeeze score
62
elevated · 0–100
Fundamentals
EPS growth
+10%
Y/Y
Free cash flow
$-132.3M
Quant / Vol
risk profile
Volatility
100%
annualized · 1-yr
Max drawdown
−54%
past year
ATR
9.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−31%
Bearish
Price vs 50-day avg
−26%
Bearish
RSI (14)
34
Neutral
MACD trend
Negative
Bearish
52-week position
6%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+27% holders QoQ · +52 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
19.66% of float · ▼ -19.6% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
142 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $2 · 6%
Range high $4
vs 200-day avg -31%
vs 50-day avg -26%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CABA
this stock
Cabaletta Bio, Inc.
|
$335.70M | -7.8% | — | — | 19.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +10.8% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.3% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +535.7% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CABA | +2.0% | -38.2% | -40.6% | +5.2% | -7.8% |
| SPY | +2.0% | +1.7% | +11.3% | +2.2% | +14.3% |
| vs SPY | +0.1% | -39.9% | -51.9% | +3.1% | -22.0% |